Search Videos and More
News
Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings
Dana-Farber Cancer Institute researchers presented key research studies at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy.
News
Dana-Farber Researchers Present Findings at 2025 ASCO Genitourinary Cancers Symposium
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium, on February 13-15, 2025, in San Francisco, Calif.
News
A Year of Advances in Genitourinary Cancer
Dana-Farber’s genitourinary cancer team is devoted to research that will advance patient care and improve patient’s lives. Recently, that research — all of it years in the making — has paid off with major achievements.
News
What is a Menin Inhibitor?
Menin, a protein located in the nucleus of various human cell types, often functions as a tumor suppressor by inhibiting excessive cell growth and division.
News
Dana-Farber Research News 02.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from January 1 through January 15.
News
Can Metastatic Breast Cancer Be Cured?
When Yvonne Fantaci discovered she had breast cancer at age 60, it had already spread to her lungs, liver, and elsewhere. Fantaci felt blindsided. She was otherwise completely healthy. She never expected such a shocking diagnosis.
News
Expanding Options for Patients with Ovarian Cancer
In 2021, a novel drug called belzutifan was approved by the U.S. Food and Drug Administration (FDA) to treat clear cell renal cell carcinoma, a form of kidney cancer.
News
Blood Test Could Guide Use of Anti-Inflammatory Drug Celecoxib to Reduce Risk of Colon Cancer Recurrence
A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit from adding of celecoxib, to post surgery treatment.
News
Dana-Farber Investigators Pinpoint Keys to Cell Therapy Response for Leukemia
Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission.
News
Dana-Farber Research News 01.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 through December 15.
News
Dana-Farber and Gustave Roussy Announce 2025 Transatlantic Exchange Scientific Program to Focus on Radioligand Therapy
Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Fourth Transatlantic Exchange in Oncology Conference topic will be “Radiopharmaceutical Therapy Meets Oncology.”
Video
Katie Maurer, MD, PhD discusses HSCT treatment
Katie Maurer, MD, PhD, from Dana-Farber Cancer Institute, shared #ASH24 findings suggesting that diverse bone marrow cell composition may predict treatment response in the content of AML patients undergoing HSCT.